Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 8928 results

  1. Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]

    Awaiting development Reference number: GID-TA11065 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]

    Awaiting development Reference number: GID-TA11951 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]

    Awaiting development Reference number: GID-TA11877 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]

    Awaiting development Reference number: GID-TA11952 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]

    Awaiting development Reference number: GID-TA11953 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Deucravacitinib for treating active Sjogren's syndrome [ID6715]

    Awaiting development Reference number: GID-TA11939 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    Awaiting development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development Reference number: GID-TA11224 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date: TBC

    Health technology evaluations
    In development

  11. Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

    In development Reference number: GID-TA11676 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]

    Awaiting development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]

    Awaiting development Reference number: GID-TA11966 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

    In development Reference number: GID-TA10620 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development